financetom
Business
financetom
/
Business
/
Appeals court to hear challenges to potential US TikTok ban on Sept. 16
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Appeals court to hear challenges to potential US TikTok ban on Sept. 16
Jun 17, 2024 8:34 AM

WASHINGTON (Reuters) -A U.S. appeals court on Monday said it will hold oral arguments on Sept. 16 on legal challenges to a new law requiring China-based ByteDance to divest TikTok's U.S. assets by Jan. 19 or face a ban.

On May 14, a group of TikTok creators filed suit to block the law that could ban the app used by 170 million Americans, saying it has had "a profound effect on American life" after TikTok and parent company ByteDance filed a similar lawsuit.

The hearing before the U.S. Court of Appeals for the District of Columbia will put the fate of TikTok in the middle of the final weeks of the 2024 presidential election. Earlier this month, Republican presidential candidate Donald Trump joined TikTok and he has raised concerns about a potential ban.

The creators, TikTok and ByteDance must file legal briefs by Thursday and the Justice Department by July 26, with reply briefs due by Aug. 15.

TikTok and the Justice Department have sought a ruling by Dec. 6 in order to seek review from the Supreme Court if needed.

A third legal challenge was filed on June 6 by the Liberty Justice Center, representing BASED Politics Inc., a conservative group that posts videos on TikTok.

Signed by President Joe Biden on April 24, the law gives ByteDance until Jan. 19 to sell TikTok or face a ban. The White House says it wants to see Chinese-based ownership ended on national security grounds, but not a ban on TikTok.

The law prohibits app stores like Apple and Alphabet's Google from offering TikTok and bars internet hosting services from supporting TikTok unless it is divested by ByteDance.

Driven by worries among U.S. lawmakers that China could access data on Americans or spy on them with the app, the measure was passed overwhelmingly in Congress just weeks after being introduced.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Shell Collaborates With Indonesia Government to Address Gasoline Supply Issues
Shell Collaborates With Indonesia Government to Address Gasoline Supply Issues
Oct 7, 2025
07:15 AM EDT, 10/07/2025 (MT Newswires) -- Shell (SHEL) is working with the Indonesian government and other stakeholders to restock gasoline at its fuel stations as quickly as possible, Bloomberg reported Tuesday, citing a company spokesperson. The company's retail stations in Indonesia are experiencing gasoline shortages for the second time in less than two months, due to ongoing import restrictions,...
Canadian retailer Kits Eyecare misses Q3 sales estimates
Canadian retailer Kits Eyecare misses Q3 sales estimates
Oct 7, 2025
Overview * Kits Eyecare ( KTYCF ) Q3 revenue up 25.1% yr/yr to C$52.4 mln, missing estimates * Adjusted EBITDA for Q3 increased to approximately 5.2% of revenue * New customers grew 27.6% yr/yr to about 99,000 Outlook * Company did not provide specific guidance for future quarters or year Result Drivers * CUSTOMER GROWTH - New customers increased by...
Eli Lilly Reports 4 Years of Sustained Remission in Patients With Ulcerative Colitis
Eli Lilly Reports 4 Years of Sustained Remission in Patients With Ulcerative Colitis
Oct 7, 2025
07:21 AM EDT, 10/07/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that data from its phase 3 open-label extension study showed that its drug Omvoh, or mirikizumab-mrkz, achieved sustained clinical, endoscopic and steroid-free remission over four years in patients with moderate to severely active ulcerative colitis. After four years of treatment, the company said that 78% of...
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment
Oct 7, 2025
07:23 AM EDT, 10/07/2025 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Tuesday the US Food and Drug Administration has indicated openness to a biologics license application submission for accelerated approval of its LX2006 candidate for the treatment of Friedreich ataxia cardiomyopathy. The submission will include interim clinical data from ongoing phase I/II studies of LX2006 pooled with new...
Copyright 2023-2026 - www.financetom.com All Rights Reserved